Summary: The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the use of Slenyto, a prolonged-release melatonin drug, to treat insomnia in children with neurogenetic disorders. Originally approved in 2018 for children … [Read more...]